The PennZone

WEST CHESTER, Pa., Aug. 25, 2021 /PRNewswire/ -- VESTECK, Inc., an early-stage medical device company, is pleased to announce its initial close on $4.3M of Series A financing, which includes conversion of all existing convertible notes.

The New World Angels (www.newworldangels.com) of S. Florida, led the Series A round with a $1.1 million investment.  The New Word Angels were joined by Florida-based DeepWork Capital and Ocean Azul Partners, as well as a number of Philadelphia-based investors, including Ben Franklin Technology Partners of Southeastern Pennsylvania, Robin Hood Ventures and the Delaware Crossing Investor Group. The Series A funds will support the manufacturing of products, pre-clinical testing and completion of in human procedures, prior to our clinical study for FDA clearance.

VESTECK has designed a platform technology comprised of 6 devices that integrate the delivery of nitinol sutures into a catheter, improving clinical outcomes for endovascular aortic aneurysm patients.

More on The PennZone

• Century Fasteners Corp. Exhibiting at 2026 Farnborough International Airshow
• Compton to host first Juneteenth celebration with We Are Us Festival
• Wayne Homes Refreshes Its Pittsburgh Area Model Home Center Page
• DuoKey Launches Quantum Risk Score to Help Enterprises Prioritise Post-Quantum Cryptography Migration
• Top 5 Most Reliable Used Vans in the UK in 2026

The "Suture-Tight" catheter delivers nitinol sutures more easily than current endovascular or surgical options, securing endovascular aortic repair grafts to the aorta at initial implant or in repair procedures.  Dr. David H. Deaton, Chief Medical Officer, says, "the Suture-Tight catheter makes the process faster, easier and safer for surgeons and patients.  Suture-Tight will become the standard of care."  Vesteck expects to bring significant incremental revenue to an aortic repair market projected to be $4.5B by 2028.

VESTECK CEO Joe Rafferty stated, "We are truly honored that a consortium of such distinguished early-stage investors led by New World Angels believe in our plan, our team and our technology.  We are committed to proving their trust in us was accurate by helping solve this significant unmet need."

Commenting on the investment, Steve O'Hara, president of New World Angels, said, "We are delighted to support Joe Rafferty and his team at Vesteck as they seek to improve patient outcomes for a number of less invasive surgeries, starting with endovascular aortic repair procedures."

More on The PennZone

• Dominican Fashion Designer Raiza Bonaparte presents the Sovereign Despampanante Collection at the Library of Congress
• Roohid Parast on How AI Is Changing What Bench Scientists Can Do
• What Happens When Congress Says No? New Book Examines the Boland Amendments, Iran-Contra Affair & Jamaican Posse, as US Congress Debate Over Military
• Warm, Dry Summer Forecast Points to a Stronger Wasp and Yellowjacket Season Across the Pacific Northwest
• Qscription Technologies Appoints Anurag Velekkatt Sunil Kumar to Drive Enterprise Scale

VESTECK was represented by Kevin M. Granahan of Fox Rothschild LLP.  The New World Angels were represented by Mark R. Mohler of Corridor Legal Partners, LLP.

About Vesteck Inc.:

VESTECK, Inc. (WWW.VESTECK.com) is an early-stage medical device company focused on bringing their proprietary technology to the aortic repair, structural heart and GI markets.

Their first product, the "Suture-Tight" nitinol suture delivery catheter will bring a novel technology to endovascular aortic repair market solving a significant global challenge for physicians and patients.

MEDIA CONTACTS:
New World Angels	VESTECK, Inc.
Sarah Lucas	Joe Rafferty
COO	CEO
(617) 894-5156	610-457-7324

SOURCE VESTECK, Inc.

Related Links

http://VESTECK.com

---

Show All News | Disclaimer | Report Violation